quaternary 1,1-diphenyl-4-pyrrolidinium-2-butyne salts corresponding to the following general formula ##STR1## in which R represents methyl or ethyl and X is a chlorine or bromine atom, are described. These compounds are distinguished by improved spasmolytic and broncholytic activity.
|
1. A method of treating a warm-blooded mammal, comprising administering to a warm-blooded mammal an anti-ulcerogenically effective amount of a quaternary 1,1-diphenyl-4-pyrrolidinium-2-butyne salt of the formula: ##STR6## in which R represents methyl or ethyl and X is a chlorine or bromine atom, to elicit an anti-ulcerogenic response.
2. The method of
3. The method of
|
|||||||||||||||||||
This invention relates to quaternary 1,1-diphenyl-4-pyrrolidinium-2-butyne salts corresponding to the following general formula ##STR2## to a process for their production and to medicaments containing these compounds.
It is known that the phosphate of 1,1-diphenyl-4-pyrrolidino-2-butyne-1-ol (butynoline) having the following structural formula ##STR3## is pharmacologically active and shows for example anti-cholinergic spasmolytic and anti-ulcerogenic activity. By virtue of these properties, medicaments containing butynoline phosphate as their active principle are already available on the market.
It has now surprisingly been found that quaternary butynoline salts corresponding to the above formula show better pharmacological activity than the known butynoline phosphate.
Accordingly, the present invention relates to quaternary 1,1-diphenyl-4-pyrrolidinium-2-butyne salts corresponding to the following general formula ##STR4## in which R represents methyl or ethyl and X is a chlorine or bromine atom.
These salts are new compounds. Compared with the known butynoline phosphate, they show for example improved spasmolytic and broncholytic activity.
The compound 1,1-diphenyl-4-pyrrolidinyl-2-butyne-1-ol-N-methyl ammonium bromide is preferred by virtue of its pharmacological properties.
The present invention also relates to a process for preparing these quaternary salts which is characterised in that 1,1-diphenyl-4-pyrrolidino-2-butyne-1-ol corresponding to the following formula is ##STR5## is reacted in known manner with an alkylating agent corresponding to the following formula
R-X
in which R represents methyl or ethyl and X is a chlorine or bromine atom, in an aprotic or protic solvent to form the corresponding salts of formula I.
The reaction starts out from the known compound butynoline of which the production is described by J. A. Gautier and C. C. Farnoux in Bul.. Soc. Chim. France 1964, page 2147.
Quaternization of the butynoline base is carried out by standard methods of the type described for example in "Organikum, Org.-chemisches Grundpraktikum", Autorenkollektiv, VEB Deutscher Verlag der Wissenschaften, Berlin 1977, page 260. Suitable solvents for the quaternisation reaction are both protic and aprotic solvents, such as for example ethanol, nitromethane, acetonitrile and dimethyl formamide. The reaction is best carried out with a molar ratio of butynoline base to alkyl halide of from 1.1 to 1:6, preferably 1:2. The reaction is preferably carried out in an autoclave under an excess pressure of from 0.5 to 5 bars, preferably 2 bars. The reaction is carried out at temperatures in the range from 65° to 75°C and preferably at 70°. The reaction is usually over after 5 to 8 hours and normally after 7 hours. The reaction mixture is worked up by known methods, for example by distilling off the solvent, optionally in vacuo, adding an organic solvent and precipitating the product with an organic solvent miscible with that solvent. Purification is also carried out in known manner, for example by recrystallization from an organic solvent, such as ethanol, or by dissolution and reprecipitation.
As already mentioned, the compounds according to the invention show better pharmacological properties than the known butynoline phosphate, particularly in regard to the broncholytic and anti-ulcerogenic effect obtainable therewith. Tests relating to inhibition of the carbachol-induced secretion of saliva and mydriasis have shown that the compounds according to the invention have fewer side effects than the known butynoline phosphate.
The following Table summarizes the results of pharmacological studies conducted with the compound according to the invention, 1,1-diphenyl-4-pyrrolidinyl-2-butyne-1-ol-N-methyl ammonium bromide, and with butynoline phosphate as the comparison substance.
| TABLE |
| __________________________________________________________________________ |
| 1,1-diphenyl-4-pyrrolidinyl- |
| 2-butyne-1-ol-N--methyl |
| Butynoline |
| Test method |
| ammonium bromide |
| phosphate |
| (literature ref.) |
| __________________________________________________________________________ |
| Broncholysis |
| ED50 (μg/kg i.v.) |
| ED50 (μg/kg i.v.) |
| Konzett, H., |
| (guinea pig) |
| ACH 30 ACH 60 Rossler, R., |
| Hi 500 Hi 1000 Arch. exp. Pharmacol. |
| Path., 195, 71 (1940) |
| Anti-ulcerogenic |
| ED50 (mg/kg) |
| ED50 (mg/kg) |
| Takagi, K., Okabe, S., |
| effect i.g. i.g. Jap. J. Pharmac. 18, |
| stress ulcer |
| 25 150 9 (1968) |
| Inhibition of the |
| ED50 (mg/kg) |
| ED50 (mg/kg) |
| Mod. according to |
| carbachol-induced |
| i.g. i.g. Brown, D. M., Quinton, |
| secretion of |
| 24 9.8 R. M., Brit. J. Pharma- |
| saliva (rat) col. 12, 53 (1957) |
| cholinolytic |
| side effects |
| Mydriasis ED50 (mg/kg) |
| ED50 (mg/kg) |
| Pulewka, P. Arch. |
| cholinolytic |
| i.g. i.g. exp. Pharmacol. |
| side effects |
| 128 16 Path. 168, 307 (1932) |
| Spasmolytic effect |
| pA2 (ACH) |
| pA2 (ACH) |
| Van Rossum, J. M., |
| in vitro (Mee-ileum) |
| 8.0 8.2 Arch. Int. Pharmaco- |
| dyn. Ther. 143, |
| 299 (1963) |
| Inhibition of the |
| ED50 (mg/kg) |
| ED50 (ACH) |
| Engler, H., Fritschi, |
| carbachol-induced |
| i.g. i.g. E., Naunyn |
| gastric secretion |
| 0.3 0.3 Schmiedeberg's Arch. |
| (Heidenhain cat) Pharmacol. 297, |
| R 43 (1977) |
| __________________________________________________________________________ |
Accordingly, the present invention also relates to a medicament, particularly a spasmolytic and anti-ulcerogenic agent, which is characterized in that it contains a quaternary salt of the type defined above in addition to standard auxiliaries and excipients.
The medicaments according to the invention may be made into pharmaceutical preparations with direct or delayed release of the active principle in admixture with an organic excipient or inorganic inert excipient suitable for oral or parenteral application, for example calcium hydrogen phosphate, cellulose, dextrose, corn starch, saccharose, magnesium stearate, lactose, gelatin, polyvinyl pyrrolidine, vegetable oils, polyethylene glycol, vaseline, etc. The medicament according to the invention may be made up in solid form, for example in the form of tablets or capsules, in the form of a solution, suspension or emulsion or in the form of suppositories. In addition, the medicament according to the invention may form the active principle of a tea preparation known per se. With peroral administration, the individual dose, based on the active principle, amounts to between 5 and 50 mg and preferably to between 10 and 30 mg. The daily dose may be administered in one or more individual doses.
The invention is illustrated by the following Example.
PAC Preparation of 1,1-diphenyl-4-pyrrolidinyl-2-butyne-1-ol-N-methyl ammonium bromide29.1 g (0.1 mole) of 1,1-diphenyl-4-pyrrolidino-2-butyne-1-ol are initially introduced into a 0.5-liter laboratory autoclave, suspended while stirring in 140 ml of dimethyl formamide and the resulting suspension cooled with acetone/dry ice to approximately -40°C 19.0 g (0.2 mole) of methyl bromide are then added and the autoclave is closed.
After heating for 7 hours with stirring to 70°C, the reaction mixture is left to cool and the dimethyl formamide is evaporated off in a water jet pump vacuum in a rotary evaporator. 30 ml of 99.7% ethanol are then added and dissolved in a water bath heated to 60°C 50 ml of ethyl acetate are slowly added with stirring to the resulting solution which is then left standing to crystallize.
After filtration under suction, the product is recrystallized by dissolution under heat in 50 ml of 99.7% ethanol, cooling to +10° C. and adding 60 ml of ethyl acetate and 30 ml of diethyl ether. The residue is filtered under suction and dried in air.
Thin-layer chromatography (100% CH3 OH) 1 patch.
Melting point: 147.8°C-148.7°C
Yield: 30.6 g=79.2% of the theoretical.
Liebenow, Walter, Liedtke, Hans
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 2584429, | |||
| 3051714, | |||
| 4001328, | Jun 04 1975 | Eli Lilly and Company | Diarylbutanolamines |
| CA601311, | |||
| FR2142M, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Mar 09 1981 | LIEBENOW WALTER | LUDWIG HEUMANN & CO GMBH | ASSIGNMENT OF ASSIGNORS INTEREST | 003873 | /0669 | |
| Mar 09 1981 | LIEDTKE HANS | LUDWIG HEUMANN & CO GMBH | ASSIGNMENT OF ASSIGNORS INTEREST | 003873 | /0669 | |
| Mar 13 1981 | Ludwig Heumann & Co. GmbH | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Jul 14 1987 | REM: Maintenance Fee Reminder Mailed. |
| Dec 13 1987 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Dec 13 1986 | 4 years fee payment window open |
| Jun 13 1987 | 6 months grace period start (w surcharge) |
| Dec 13 1987 | patent expiry (for year 4) |
| Dec 13 1989 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Dec 13 1990 | 8 years fee payment window open |
| Jun 13 1991 | 6 months grace period start (w surcharge) |
| Dec 13 1991 | patent expiry (for year 8) |
| Dec 13 1993 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Dec 13 1994 | 12 years fee payment window open |
| Jun 13 1995 | 6 months grace period start (w surcharge) |
| Dec 13 1995 | patent expiry (for year 12) |
| Dec 13 1997 | 2 years to revive unintentionally abandoned end. (for year 12) |